Clinical Effect of alpha 1D/A adrenoceptor inhibitor naftopidil on Benign Prostatic Hyperplasia: An International Prostate Symptom Score and King's Health Questionnaire assessment

Abstract

Objectives:To examine the effect of alpha 1D/A adrenoceptor inhibitor naftopidil on health-related quality of life (QOL) in men with benign prostatic hyperplasia (BPH). Methods: A total of 56 newly diagnosed patients with symptomatic BPH were prospectively enrolled and treated with 50 mg naftopidil daily for more than 12 weeks. All underwent pre-treatment documentation of lower urinary tract symptoms, QOL assessment using the international prostate symptom score (IPSS) and King's Health Questionnaire (KHQ), and uroflowmetry. A post-treatment assessment was performed at 12 weeks. Results: IPSS scores as well as QOL index showed a significant improvement after naftopidil administration. Similarly, all seven domains except general health perceptions and social limitations in the KHQ questionnaire were significantly improved. When dividing the patients into overactive bladder (OAB) and non-OAB groups, only the OAB group showed significant improvement in almost all the domains of KHQ. Change ratios of the IPSS were not associated with those of KHQ domain scores in the OAB group. On the other hand , in the non-OAB group more domains presented improvements, which were associated with those of IPSS scores. Conclusions: Twelve-week treatment with naftopidil for symptomatic BPH patients is associated with significant improvement in the IPSS, QOL index, maximum urinary flow rate, post-void residual urine volume (PVR) and almost all domains in KHQ. KHQ is useful for the evaluation of clinical response in BPH patients, particularly in those with associated OAB.

Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia

“…Naf is an α 1 ‐adrenoceptor antagonist predominantly affecting the α 1 ‐ D subtype, mainly distributed in the bladder membrane and related to storage symptoms 13 . Naf thus seems particularly promising for OAB symptoms, 14 although Naf potentially could have effects on both voiding symptoms and storage symptoms, thus avoiding the need for antimuscarinic drugs even in BPH patients with LUTS and OAB. However, this effect should be weaker for voiding symptoms compared to the α 1 ‐adrenoceptor antagonist, α 1 ‐ A subtype, because the α 1 ‐adrenoceptor α 1 ‐ A subtype is mainly located in the urethra, not the bladder 15 .…”

Naftopidil for the treatment of benign prostate hyperplasia: a systematic review

“…Also, the capacity of naftopidil to ameliorate nocturia and sleep disturbances and significantly reduce nocturnal urine volume was described by Yokoyama et al 38 . A previous study 39 , focusing on health-related QoL (HRQoL), described significant improvement of IPSS and King's Health Questionnaire Score domains after 12 weeks of treatment with naftopidil, particularly for patients with overactive bladder. A recent study of Komiya and colleagues 40 …”

Lower urinary tract symptoms and their impact on quality of life after successful renal transplantation

“…In fact, RTX patients are educated to take care of fluid intake and they may enjoy a life without need for renal replacement therapy. KHQ is useful to assess the detailed urination-related QOL status of men and women with LUTS, 13 while KHQ was originally designed and has been recommended as a disease-specific QOL questionnaire for female urinary incontinence. Hence, we used QOL score and KHQ to evaluate urination-related QOL in the present study, although they might be limited to reflect urination-related QOL in RTX patients.…”